Watanabe Yosuke, Kuroki Taiyo, Ichikawa Daisuke, Ozone Motohiro, Uchimura Naohisa, Ueno Taro
SUSMED, Inc., Tokyo, Japan.
Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan.
Sleep. 2023 Mar 9;46(3). doi: 10.1093/sleep/zsac270.
This study assessed the effects and safety of the smartphone-based cognitive behavioral therapy for insomnia (CBT-I) app compared with the sham app.
In this multicenter, double-blind, and parallel-group study, 175 patients with insomnia were randomized to a smartphone-based CBT-I app (Active, n = 87) or a sham app (Sham, n = 88) group. The primary endpoint was the change in Athens Insomnia Score (AIS) from baseline after 8 weeks of treatment.
The change in AIS (mean ± standard deviation) from baseline, assessed using a modified-intent-to-treat analysis, was -6.7 ± 4.4 in the Active group and -3.3 ± 4.0 in the Sham group. The difference in the mean change between the groups was -3.4 (p < .001), indicating a greater change in the Active group. The change in CGI-I from the baseline was 1.3 ± 0.8 in the Active group and 0.7 ± 0.8 in the Sham group (p < .001). The proportion of patients with an AIS less than 6 was 37.9% in the Active group and 10.2% in the Sham group (p < .001). As for the safety assessment, no adverse reactions or device failures were detected in the Active group.
This study demonstrated the effectiveness of a smartphone-based CBT-I system for treating insomnia.
ID: jRCT2032210071; trial name: Sham (software)-controlled, multicenter, dynamic allocation, double-blinded study of non-medication therapy with a software Yukumi in patients with insomnia disorders (verification study); URL: https://jrct.niph.go.jp/en-latest-detail/jRCT2032210071.
本研究评估了基于智能手机的失眠认知行为疗法(CBT-I)应用程序与模拟应用程序相比的效果和安全性。
在这项多中心、双盲、平行组研究中,175名失眠患者被随机分为基于智能手机的CBT-I应用程序组(干预组,n = 87)或模拟应用程序组(对照组,n = 88)。主要终点是治疗8周后雅典失眠量表(AIS)较基线的变化。
采用改良意向性分析评估,干预组AIS较基线的变化(均值±标准差)为-6.7±4.4,对照组为-3.3±4.0。两组间平均变化的差异为-3.4(p < .001),表明干预组变化更大。干预组CGI-I较基线的变化为1.3±0.8,对照组为0.7±0.8(p < .001)。AIS小于6的患者比例在干预组为37.9%,对照组为10.2%(p < .001)。至于安全性评估,干预组未检测到不良反应或设备故障。
本研究证明了基于智能手机的CBT-I系统治疗失眠的有效性。
编号:jRCT2032210071;试验名称:Sham(软件)对照、多中心、动态分配、双盲的Yukumi软件非药物治疗失眠症患者的研究(验证研究);网址:https://jrct.niph.go.jp/en-latest-detail/jRCT2032210071 。